| Description | PEG300 (Polyethylene glycol 300) is a polymer formed from repeating units of ethylene glycol that is water soluble, low immunogenicity, and biocompatible. PEG300 is a neutral polymer with a molecular weight of 300. |
| In vitro | 方法：人结直肠腺癌细胞 Caco-2 用 PEG300 (30 w/v% in 100 μL) 处理 30 min，使用 MTT 方法检测细胞生长抑制情况。结果：PEG300 处理严重降低了细胞活力，细胞生存率仅为 20%。[1] |
| In vivo | 方法：为研究 Dasatinib 对糖尿病心肌病的影响，将 Dasatinib (5 mg/kg in 10% DMSO + 90% PEG-300) 灌胃给药给 BKS.Cg-+Leprdb/+Leprdb/OlaHsd (db/db) 小鼠，每周一次，持续四周。结果：Dasatinib 可以对抗心脏和骨髓的肥胖以及心脏纤维化。[2]方法：为测试 ALW-II-41-27（一种 EPHA2 抑制剂）和/或 cetuximab 治疗的体内效果，将 cetuximab (25 mg/kg in 10% 1-methyl-2-pyrrolidinone + 90% PEG 300，每周两次) 和 ALW-II-41-27（30 mg/kg/天）腹腔注射给携带人结直肠腺癌肿瘤 HCT15 的 balb/c athymic (nu+/nu+) 小鼠，持续六周。结果：ALW-II-41-27 和 cetuximab 联合治疗显著抑制肿瘤生长。[3] |
| Synonyms | 聚乙二醇, Polyethylene glycol 300 |
| molecular weight | 300 |
| CAS | 25322-68-3 |
| Storage | store at 4°C | Shipping with blue ice. |
| Solubility | DMSO: 100 mg/mL (333.33 mM), Sonication is recommended. H2O: 50 mg/mL (166.67 mM) |
| References | 1. Pham Le Khanh H, et al. Comparative Investigation of Cellular Effects of Polyethylene Glycol (PEG) Derivatives. Polymers (Basel). 2022 Jan 11;14(2):279. 2. Gu Y, et al. The tyrosine kinase inhibitor Dasatinib reduces cardiac steatosis and fibrosis in obese, type 2 diabetic mice. Cardiovasc Diabetol. 2023 Aug 17;22(1):214. 3. Martini G, et al. EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer. Mol Cancer Ther. 2019 Apr;18(4):845-855. |
| Citations | 1. Hu Y, Wen Q, Cai Y, et al. Alantolactone induces concurrent apoptosis and GSDME-dependent pyroptosis of anaplastic thyroid cancer through ROS mitochondria-dependent caspase pathway. Phytomedicine. 2022: 154528. 2. Guo Y, Zhu L, Duan Y, et al.Ruxolitinib induces apoptosis and pyroptosis of anaplastic thyroid cancer via the transcriptional inhibition of DRP1-mediated mitochondrial fission.Cell Death & Disease.2024, 15(2): 125. |